Femasys Inc.
Tracked across 2 events · 12 articles · First seen Aug 07, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Femasys Inc., a biomedical company developing fertility and non-surgical permanent birth control solutions, announced on August 7, 2026 that it entered into a securities purchase agreement for a $30 million private placement with accredited investors.…
Impact: Femasys is the issuer of the private placement, raising $30 million with potential additional proceeds. The financing strengthens its balance sheet and supports its business plan, but the stock price declined due to dilution.
Aug 07, 2026 · 6 articles
Regulatory
Femasys Inc. announced that the U.S. United States — Food and Drug Administration (FDA) has approved the company's modular premarket approval (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology. This approval allows…
Impact: Femasys is the developer of FemBloc and the recipient of the FDA's approval of the modular PMA pathway. This approval is a major step toward U.S. commercialization, positively impacting the company's prospects and stock price.
Aug 19, 2026 · 6 articles
100
Femasys Inc. entered intoFemasys $30M Private...
100
United States — Food and Drug Administration approved modular PMA pathway Femasys Inc.FDA Approves FemBloc...
90
Femasys Inc. issued sharesFemasys $30M Private...
80
Nantahala Capital Management led financing Femasys Inc.Femasys $30M Private...
60
Femasys Inc. agreed to file United States — United States Securities and Exchange CommissionFemasys $30M Private...
50
Rosalind Advisors participated in Femasys Inc.Femasys $30M Private...
ERGEN INTELLIGENCE
Track Femasys Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard